Novavax applies for COVID-19 vaccine approval in Switzerland
Novavax applies for COVID-19 vaccine approval in Switzerland

Novavax applies for COVID-19 vaccine approval in Switzerland

A woman holds a small bottle labeled with a “Coronavirus COVID-19 Vaccine” label and a medical syringe in front of the Novavax logo shown in this illustration taken, October 30, 2020. REUTERS / Dado Ruvic

Sign up now for FREE unlimited access to Reuters.com

February 14 (Reuters) – Novavax Inc (NVAX.O) has submitted an application to the Swiss Anti-Doping Agency for approval of their COVID-19 vaccine for adults, the U.S. vaccine maker said Monday.

The submission is based on data from two important clinical trials in the United States and Mexico, as well as in the United Kingdom, which showed that the vaccine was 90% effective against COVID-19.

Novavax’s protein-based vaccine is being reviewed by the US Food and Drug Administration and has received approvals from the EU and the World Health Organization.

It has also been approved for use in adults in countries including the UK, New Zealand and Australia. The company said last week that its vaccine was about 80% effective at a late stage of trials in adolescents.

Sign up now for FREE unlimited access to Reuters.com

Reporting by Amruta Khandekar in Bengaluru; Editing by Arun Koyyur

Our standards: Thomson Reuters trust principles.

Leave a Reply

Your email address will not be published.